Surgical Endoscopy

, Volume 30, Issue 12, pp 5542–5549 | Cite as

Is preoperative withdrawal of aspirin necessary in patients undergoing elective inguinal hernia repair?

  • Wilson Ong
  • Tong Shen
  • Wee Boon Tan
  • Davide Lomanto
Article
First Online:
Received:
Accepted:

Abstract

Background

Antiplatelets such as aspirin are widely used to reduce thrombotic events in patients with various cardiovascular comorbidities. Continuing aspirin through noncardiac surgery has been shown to reduce risk of major adverse cardiac events (MACE) but may lead to higher bleeding complications. Inguinal hernia repair is a commonly performed surgical procedure among such patients, but no guideline exists regarding perioperative use of aspirin.

Objective

We aim to investigate the safety profile of aspirin continuation in the perioperative period in patients undergoing elective primary inguinal hernia repair.

Methods

All patients who underwent elective primary inguinal hernia repair from 2008 to 2015 and were on aspirin preoperatively were identified. The patients were divided into two groups: those who continued aspirin through the morning of the operation and those who were advised to stop aspirin therapy 3–7 days prior to operation. All patients underwent either open Lichtenstein mesh repair or laparoscopic total extra-peritoneal mesh repair. Outcomes measured include intraoperative blood loss, operative time, bleeding complications, wound site complications and MACE.

Results

Among 1841 patients who underwent elective primary inguinal hernia mesh repair, 142 (7.7 %) patients were on preoperative aspirin. Fifty-seven patients underwent laparoscopic repair, while 85 underwent open mesh repair. Twenty-seven out of fifty-seven (47.3 %) from the laparoscopic group and 55/85 (64.7 %) from the open group were instructed to stop aspirin (p = 0.040). There were no significant differences between those who stopped aspirin and those who continued in terms of intraoperative blood loss and operative timing. Immediate postoperative bleeding complications and follow-up wound complications were also similar between the two groups. Overall, there were no MACE among those who underwent laparoscopic repair. Three MACE were recorded in the open group (2 stopped vs. 1 continued; p = 0.943). There was no perioperative mortality.

Conclusion

Continuation of aspirin is safe and should be preferred in patients with higher cardiovascular risk.

Keywords

Antiplatelets Aspirin Inguinal hernia Repair 
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical standards

Disclosure

Drs. Wilson Ong, Shen Tong, Tan Wee Boon and Davide Lomanto have no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Yusuf S, Reddy S, Ounpuu S, Anand S (2001) Global burden of cardiovascular diseases part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104:2746–2753CrossRefPubMedGoogle Scholar
  2. 2.
    Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt GH (2005) Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 173:627–634CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110:255–258CrossRefPubMedGoogle Scholar
  4. 4.
    Jimenez AH, Stubbs ME, Tofler GH, Winther K, Williams GH, Muller JE (1992) Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 69:258–262CrossRefPubMedGoogle Scholar
  5. 5.
    Mahla E, Lang T, Vicenzi MN, Werkgartner G, Maier R, Probst C, Metzler H (2001) Thromboelastography for monitoring prolonged hypercoagulability after major abdominal surgery. Anesth Analg 92:572–577CrossRefPubMedGoogle Scholar
  6. 6.
    Samama CM, Thiry D, Elalamy I, Diaby M, Guillosson JJ, Kieffer E, Coriat P (2001) Perioperative activation of hemostasis in vascular surgery patients. Anesthesiology 94:74–78CrossRefPubMedGoogle Scholar
  7. 7.
    Oscarsson A, Gupta A, Fredrikson M, Jarhult J, Nystrom M, Pettersson E, Darvish B, Krook H, Swahn E, Eintrei C (2010) To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 104:305–312CrossRefPubMedGoogle Scholar
  8. 8.
    Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, Leslie K, Rao-Melacini P, Chrolavicius S, Yang H, Macdonald C, Avezum A, Lanthier L, Hu W, Yusuf S, Investigators P (2011) Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med 154:523–528CrossRefPubMedGoogle Scholar
  9. 9.
    Devereaux PJ, Goldman L, Yusuf S, Gilbert K, Leslie K, Guyatt GH (2005) Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ 173:779–788CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Welsch T, Eisele H, Zschabitz S, Hinz U, Buchler MW, Wente MN (2011) Critical appraisal of the International Study Group of Pancreatic Surgery (ISGPS) consensus definition of postoperative hemorrhage after pancreatoduodenectomy. Langenbecks Arch Surg 396:783–791CrossRefPubMedGoogle Scholar
  11. 11.
    Wei AC, Tung-Ping Poon R, Fan ST, Wong J (2003) Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg 90:33–41CrossRefPubMedGoogle Scholar
  12. 12.
    Korte W, Cattaneo M, Chassot PG, Eichinger S, von Heymann C, Hofmann N, Rickli H, Spannagl M, Ziegler B, Verheugt F, Huber K (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 105:743–749CrossRefPubMedGoogle Scholar
  13. 13.
    Wolf AM, Pucci MJ, Gabale SD, McIntyre CA, Irizarry AM, Kennedy EP, Rosato EL, Lavu H, Winter JM, Yeo CJ (2014) Safety of perioperative aspirin therapy in pancreatic operations. Surgery 155:39–46CrossRefPubMedGoogle Scholar
  14. 14.
    Antithrombotic Trialists C (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRefGoogle Scholar
  15. 15.
    Rodondi N, Cornuz J (2006) The role of aspirin in the primary prevention of cardiovascular disease. Rev Med Suisse 2:646–651PubMedGoogle Scholar
  16. 16.
    Harrington RA, Becker RC, Ezekowitz M, Meade TW, O’Connor CM, Vorchheimer DA, Guyatt GH (2004) Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:513S–548SCrossRefPubMedGoogle Scholar
  17. 17.
    Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI (2004) Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:576S–599SCrossRefPubMedGoogle Scholar
  18. 18.
    Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE (2000) Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 35:1288–1294CrossRefPubMedGoogle Scholar
  19. 19.
    Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H (2006) Coronary artery stenting and non-cardiac surgery—a prospective outcome study. Br J Anaesth 96:686–693CrossRefPubMedGoogle Scholar
  20. 20.
    Beving H, Zhao C, Albage A, Ivert T (1996) Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatment. Blood Coagul Fibrinolysis 7:80–84CrossRefPubMedGoogle Scholar
  21. 21.
    Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 27:2667–2674CrossRefPubMedGoogle Scholar
  22. 22.
    Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I (2012) Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg 255:811–819CrossRefPubMedGoogle Scholar
  23. 23.
    Burger W, Chemnitius JM, Kneissl GD, Rucker G (2005) Low-dose aspirin for secondary cardiovascular prevention—cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation—review and meta-analysis. J Intern Med 257:399–414CrossRefPubMedGoogle Scholar
  24. 24.
    Tytgat SH, Laman DM, Rijken AM, Klicks R, Voorwinde A, Ultee JM, Van Duijn H (2005) Emboli rate during and early after carotid endarterectomy after a single preoperative dose of 120 mg acetylsalicylic acid—a prospective double-blind placebo controlled randomised trial. Eur J Vasc Endovasc Surg 29:156–161CrossRefPubMedGoogle Scholar
  25. 25.
    Ferraris VA, Swanson E (1983) Aspirin usage and perioperative blood loss in patients undergoing unexpected operations. Surg Gynecol Obstet 156:439–442PubMedGoogle Scholar
  26. 26.
    Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Acc Aha Task, Force M, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW (2007) ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 116:1971–1996CrossRefPubMedGoogle Scholar
  27. 27.
    Merritt JC, Bhatt DL (2004) The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis 17:21–27CrossRefPubMedGoogle Scholar
  28. 28.
    Chassot PG, Delabays A, Spahn DR (2007) Perioperative use of anti-platelet drugs. Best Pract Res Clin Anaesthesiol 21:241–256CrossRefPubMedGoogle Scholar
  29. 29.
    O’Riordan JM, Margey RJ, Blake G, O’Connell PR (2009) Antiplatelet agents in the perioperative period. Arch Surg 144:69–76 (discussion 76) CrossRefPubMedGoogle Scholar
  30. 30.
    Juul P, Christensen K (1999) Randomized clinical trial of laparoscopic versus open inguinal hernia repair. Br J Surg 86:316–319CrossRefPubMedGoogle Scholar
  31. 31.
    McCormack K, Scott NW, Go PM, Ross S, Grant AM, Collaboration the EU Hernia Trialists (2003) Laparoscopic techniques versus open techniques for inguinal hernia repair. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD001785
  32. 32.
    Harder S, Klinkhardt U, Alvarez JM (2004) Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 43:963–981CrossRefPubMedGoogle Scholar
  33. 33.
    Enver MK, Hoh I, Chinegwundoh FI (2006) The management of aspirin in transurethral prostatectomy: current practice in the UK. Ann R Coll Surg Engl 88:280–283CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Joseph B, Rawashdeh B, Aziz H, Kulvatunyou N, Pandit V, Jehangir Q, O’Keeffe T, Tang A, Green DJ, Friese RS, Rhee P (2015) An acute care surgery dilemma: emergent laparoscopic cholecystectomy in patients on aspirin therapy. Am J Surg 209:689–694CrossRefPubMedGoogle Scholar
  35. 35.
    Lee J, Kim JK, Kim JH, Dunuu T, Park SH, Park SJ, Kang JY, Choi RK, Hyon MS (2014) Recovery time of platelet function after aspirin withdrawal. Curr Ther Res Clin Exp 76:26–31CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zisman E, Erport A, Kohanovsky E, Ballagulah M, Cassel A, Quitt M, Pizov R (2010) Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. Eur J Anaesthesiol 27:617–623CrossRefPubMedGoogle Scholar
  37. 37.
    Sonksen JR, Kong KL, Holder R (1999) Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br J Anaesth 82:360–365CrossRefPubMedGoogle Scholar
  38. 38.
    Faraday N, Becker DM, Becker LC (2007) Pharmacogenomics of platelet responsiveness to aspirin. Pharmacogenomics 8:1413–1425CrossRefPubMedGoogle Scholar
  39. 39.
    Fogari R, Zoppi A (2005) Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant? Am J Cardiovasc Drugs 5:211–223CrossRefPubMedGoogle Scholar
  40. 40.
    Sudic D, Razmara M, Forslund M, Ji Q, Hjemdahl P, Li N (2006) High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 133:315–322CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Wilson Ong
    • 1
  • Tong Shen
    • 1
  • Wee Boon Tan
    • 2
  • Davide Lomanto
    • 2
  1. 1.Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore
  2. 2.Department of Surgery, Minimally Invasive Surgical Centre, National University Health System, Yong Loo Lin School of MedicineNational University of SingaporeSingaporeSingapore

Personalised recommendations